Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of Rodrigo M. Burgos

Rodrigo M. Burgos


Clinical Assistant Professor, College of Pharmacy
HIV Residency (PGY3) Director, College of Pharmacy
ID Residency (PGY2) Director, University of Illinois at Chicago

Contact

Office Phone:

(312) 996-1654 (mobile)

Related Sites:

About Heading link

Research Interests:
Infectious diseases, virology, HIV, CMV, COVID-19, immunocompromised, opportunistic infections, pharmacoepidemiology

Teaching and Supervision Heading link

PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
Spanish for Pharmacists (PMPR 337), 8/23/2021 – 12/3/2021
Spanish for Pharmacists (PMPR 337), 8/23/2021 – 12/3/2021
PDAT 6: Infectious Diseases (PHAR 506), 1/11/2021 – 4/30/2021
PDAT 6: Infectious Diseases (PHAR 506), 1/11/2021 – 4/30/2021

Selected Grants

CTA - Observational Cohort Study of Cabenuva Utilization, Outcomes, and Patient Experience in the United States (BEYOND), Research Triangle Inst., 9/30/2021 - 3/29/2022, Obligated Amount: $28904; Anticipated Amount: $28904

COVID19 CTA: CoVPN 3003 :A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults..., FHI Development 360 LLC., 8/15/2020 - 8/31/2022, Obligated Amount: $1274900; Anticipated Amount: $1274900

Advanced Manufacturing Technology (AMT) and Cybersecurity Study, Il Manufacturing Excellence Ctr., 2/1/2020 - 12/31/2020, Obligated Amount: $99456; Anticipated Amount: $99456

Merck Investigator Initiated Studies Program., 10/2019 - 7/22/2022, Obligated Amount: $125941.25; No Anticipated Amount Set

Merck Investigator Initiated Studies Program., 10/2019 - 7/22/2022, Obligated Amount: $125941.25; No Anticipated Amount Set

Elbasvir/grazoprevir (Zepatier) for HCV Treatment in Patients with Substance Use, Merck & Co., Inc.., 2019 - Present, No Obligated Amount Set; No Anticipated Amount Set

Merck 1439A-021 Phase III Clinical Trial to Evaluate MK-1439A vs Atripla in Treatment Na�ve Persons Infected with HIV-1, Merck Sharp & Dohme LLC., 9/22/2015 - 6/30/2018, Obligated Amount: $102044; Anticipated Amount: $102044

Merck 1439A-024 Randomized Study to Evaluate Switch to MK-143A in HIV-1 Infected Subjects on Reigmen of Ritonavir-Boosted Protease Inhimitor and Two NRTIs, Merck Sharp & Dohme LLC., 8/18/2015 - 5/29/2017, Obligated Amount: $267180; Anticipated Amount: $267180

Gilead 366-1160 Phase 3b ARV Switch Study: Atripla to FTC/RPV/TAF FDC in HIV1-Infected, Virologically Suppressed Persons, Gilead Sciences., 7/21/2015 - 12/31/2017, Obligated Amount: $134214; Anticipated Amount: $134214

Selected Publications

Lora, Alfredo J Mena, Echeverria, Stephanie L, Herald, Fischer, McSweeney, James, Gumasana, Harshil, Burgos, Rodrigo M, Borgetti, Scott. (2021). 558. Implementation and Outcomes of a COVID-19 Monoclonal Antibody Treatment Program in an Urban Safety-net Community Hospital. Open Forum Infectious Diseases, 8, (Suppl 1), s381-s381. doi:10.1093/ofid/ofab466.756.

Lora, Alfredo Mena, Li, Ella, Herald, Fischer, Simpkins, Nichelle, Krill, Candice, Takhsh, Eden, Burgos, Rodrigo, Marchionne, John, Ali, Mirza, Spencer, Sherrie, Bleasdale, Susan, Borgetti, Scott. (2021). Impact of COVID-19 on Antimicrobial Use and Resistance in an Urban Safety-Net Community Hospital. Antimicrobial Stewardship & Healthcare Epidemiology, 1, (S1), s17-s18. doi:10.1017/ash.2021.32.

Mena Lora, Alfredo, Burgos, Rodrigo, Li, Ella, Simpkins, Nichelle, Herald, Fischer, Marchionne, John, Ali, Mirza, Takhsh, Eden, Spencer, Sherrie, Krill, Candice, Bleasdale, Susan, Borgetti, Scott. (2021). Selection and Duration of Therapy as a Target for Antimicrobial Stewardship during COVID-19: Levees for a Hundred-Year Flood. Antimicrobial Stewardship & Healthcare Epidemiology, 1, (S1), s17-s17. doi:10.1017/ash.2021.31.

Michienzi, Sarah M, Johnson, Mikayla, Chiampas, Thomas D, Wenzler, Eric, Burgos, Rodrigo M, Smith, Renata O, Badowski, Melissa E. (2021). Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Drugs in Context, 10, 2021-2-1. doi:10.7573/dic.2021-2-1.

Burgos, Rodrigo M, Badowski, Melissa E, Drwiega, Emily, Ghassemi, Samaneh, Griffith, Nikki, Herald, Fischer, Johnson, Mikayla, Smith, Renata O, Michienzi, Sarah M. (2021). The race to a COVID-19 vaccine: opportunities and challenges in development and distribution. Drugs in Context, 10, 2020-12-2. doi:10.7573/dic.2020-12-2.

Burgos, Rodrigo, Erdman, Sharon, Rodvold, Keith A. (2020). Infectious Diseases: Bacteria. Basic Skills in Interpreting Laboratory Data. American Society of Health-System Pharmacists.

Burgos, Rodrigo, Erdman, Sharon, Rodvold, Keith A. (2020). Infectious Diseases: Fungi, Viruses, and Myobacteria. Basic Skills in Interpreting Laboratory Data. American Society of Health-System Pharmacists.

Brizzi, Marisa B, Burgos, Rodrigo M, Chiampas, Thomas D, Michienzi, Sarah M, Smith, Renata, Yanful, Paa Kwesi, Badowski, Melissa E. (2020). Impact of Pharmacist-Driven Antiretroviral Stewardship and Transitions of Care Interventions on Persons With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 7, (8), ofaa073. doi:10.1093/ofid/ofaa073.

Burgos, Rodrigo, Michienzi, Sarah. (2020). HIV Infection: The Antiretroviral-Naïve Patient Level II. Pharmacotherapy Casebook: A Patient-Focused Approach, Eleventh Edition. McGraw-Hill Education / Medical.

Professional Leadership

Panel Member, Section Review Group, NIH-CDC-HIVMA/IDSA, 5/10/2021 - Present

SIDP Taskforce of Diversity, Equity and Inclusion, Society of Infectious Diseases Pharmacists, 1/1/2020 - Present

SIDP Fundraising Committee, 12/20/2019 - Present

Education

Degrees:
Doctor of Pharmacy (Pharm.D.), University of Illinois at Chicago, United States, 2005
Master of Public Health (MPH), University of Illinois at Chicago, United States

Postgraduate Training:
HIV/Infectious Diseases Residency, University of Illinois at Chicago, United States, 2007
Pharmacy Practice Residency, University of Illinois at Chicago, United States, 2006
Chemistry BS Program Completion, University of Illinois at Chicago, United States, 2001
Pre-Pharmacy Program, Truman College, United States, 2000
Chemistry and Pharmacy Program, University of Honduras at Tegucigalpa, Honduras, 1998

Licensures and Certifications

Pharmacist, American Academy of HIV Medicine HIV Pharmacist, 2015 - Present
HIV Expert, American Academy of HIV Medicine HIV Expert, 2008 - Present